Zoetis (NYSE:ZTS) (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering. Since becoming independent, the company has expanded its capabilities through internal research and development and strategic acquisitions, broadening its diagnostics, biotechnology and product pipelines. Its product portfolio spans both companion animal brands and large-animal solutions, and it also provides technical services, training and digital tools intended to help veterinarians and producers manage herd health and clinical decisions.
Headquartered in Parsippany, New Jersey, Zoetis operates globally with commercial and manufacturing presence across North America, Europe, Latin America and the Asia Pacific region, serving customers in numerous international markets. The company is led by a senior management team focused on innovation, regulatory compliance and expanding access to animal health solutions; Kristin Peck serves as Chief Executive Officer. Zoetis emphasizes investment in research, manufacturing capabilities and partnerships to address evolving animal-health challenges and support food security, animal welfare and the veterinary profession.
